Comparison between Nephrocare Health IPO and Sahajanand Medical Technologies IPO.
Nephrocare Health IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Sahajanand Medical Technologies IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Nephrocare Health IPO is up to ₹871.05 Cr whereas the issue size of the Sahajanand Medical Technologies IPO is up to ₹0.00 Cr. The final issue price of Nephrocare Health IPO is ₹460.00 per share and of Sahajanand Medical Technologies IPO is .
| Nephrocare Health IPO | Sahajanand Medical Technologies IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹1 per share |
| Issue Price (Lower) | ₹438.00 per share | |
| Issue Price (Upper) | ₹460.00 per share | |
| Issue Price (Final) | ₹460.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ₹41.00 per share | |
| Market Lot Size | 32 shares | |
| Fresh Issue Size | 76,89,918 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹353.60 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 1,12,53,102 shares | 2,76,44,231 shares |
| OFS Issue Size (Amount) | up to ₹517.45 Cr | up to ₹0.00 Cr |
| Issue Size Total | 1,89,43,020 shares | 2,76,44,231 shares |
| Issue Size Total (Amount) | up to ₹871.05 Cr | up to ₹0.00 Cr |
Nephrocare Health IPO opens on Dec 10, 2025, while Sahajanand Medical Technologies IPO opens on . The closing date of Nephrocare Health IPO and Sahajanand Medical Technologies IPO is Dec 12, 2025, and , respectively.
| Nephrocare Health IPO | Sahajanand Medical Technologies IPO | |
|---|---|---|
| Anchor Bid Date | Dec 09, 2025 | |
| Issue Open | Dec 10, 2025 | |
| Issue Close | Dec 12, 2025 | |
| Basis Of Allotment (Tentative) | Dec 15, 2025 | |
| Initiation of Refunds (Tentative) | Dec 16, 2025 | |
| Credit of Share (Tentative) | Dec 16, 2025 | |
| Listing date (Tentative) | Dec 17, 2025 | |
| Anchor Lockin End date 1 | Jan 13, 2026 | |
| Anchor Lockin End date 2 | Mar 14, 2026 |
Nephrocare Health IPO P/E ratio is 63.52, as compared to Sahajanand Medical Technologies IPO P/E ratio of .
| Nephrocare Health IPO | Sahajanand Medical Technologies IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Nephrocare Health Services Ltd.'s revenue increased by 34% and profit after tax (PAT) rose by 91% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Sahajanand Medical Technologies Ltd.'s revenue increased by 14% and profit after tax (PAT) rose by 442% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 78.90 | 40.92 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 71.49 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 63.52 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹4615.34 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 13.45% | 3.68% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 18.67% | 10.37% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹7.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 13.19% | 3.73% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Nephrocare Health IPO Retail Individual Investors (RII) are offered 66,00,907 shares while in Sahajanand Medical Technologies IPO retail investors are offered 66,00,907 shares. Qualified Institutional Buyers (QIB) are offered 37,71,946 shares in Nephrocare Health IPO and 0 shares in Sahajanand Medical Technologies IPO.
| Nephrocare Health IPO | Sahajanand Medical Technologies IPO | |
|---|---|---|
| Anchor Investor Reservation | 56,57,919 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 37,71,946 shares | 0 shares |
| NII | 28,28,960 shares | 0 shares |
| RII | 66,00,907 shares | 0 shares |
| Employee | 83,532 shares | 0 shares |
| Others | ||
| Total | 1,89,43,264 shares | 0 shares |
Nephrocare Health IPO subscribed 14.08x in total, whereas Sahajanand Medical Technologies IPO subscribed .
| Nephrocare Health IPO | Sahajanand Medical Technologies IPO | |
|---|---|---|
| QIB (times) | 26.82x | |
| NII (times) | 24.77x | |
| Big NII (times) | 30.43x | |
| Small NII (times) | 13.46x | |
| RII (times) | 2.36x | |
| Employee (times) | 2.81x | |
| Other (times) | ||
| Total (times) | 14.08x |
